Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced the launch of the first and only generic version of Sandostatin LAR Depot, in the United States. Octreotide acetate for injectable suspension, or the generic version of Sandostatin LAR Depot, is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome.
"With today's launch of octreotide acetate for injectable suspension, Teva is providing patients a new option for this important treatment," said Ernie Richardsen, SVP U.S. Commercial Generics.
The company noted that Sandostatin LAR Depot had annual sales of $826 million as of July 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.